Relation of Matrix Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 Ratio in Peripheral Circulating CD14+Monocytes to Progression of Coronary Artery Disease

被引:51
作者
Brunner, Stefan [1 ]
Kim, Jong-Oh [1 ]
Methe, Heiko [1 ,2 ]
机构
[1] Univ Munich, Univ Hosp Grosshadern, Dept Internal Med Cardiol, Munich, Germany
[2] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA
关键词
ATHEROSCLEROTIC LESIONS; INCREASED EXPRESSION; MONONUCLEAR-CELLS; TISSUE INHIBITOR; MATRIX-METALLOPROTEINASE-9; PLAQUES; MONOCYTES; MACROPHAGES;
D O I
10.1016/j.amjcard.2009.10.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atherosclerosis is an inflammatory disease in which systemic inflammation correlates with disease activity. Matrix metalloproteinases (MMPs) contribute to collagen breakdown in atherosclerotic plaques. In the present study, we investigated whether the ratio of MMP-9 and its endogenous inhibitor, tissue inhibitor of metalloproteinase (TIMP)-1, in circulating monocytes correlates with the clinical stages of coronary artery disease. We studied 18 patients with stable angina pectoris (SAP), 14 patients with unstable angina pectoris and non-ST-segment elevation myocardial infarction (UAP/NSTEMI), 14 patients with ST-elevation myocardial infarction (STEMI), and 16 healthy controls. The protein and mRNA levels of MMP-9 and TIMP-1 in CD14 + monocytes were analyzed using real-time polymerase chain reaction and enzyme-linked immunosorbent assay. The activity of serum MMP-9 was assessed using zymography. Compared to the controls (0.07 +/- 0.01 relative units) and patients with SAP (0.25 +/- 0.1 relative units, p = NS), the monocytic MMP-9 mRNA levels were increased in those with UAP/NSTEMI (0.9 +/- 0.3 relative units, p <0.05 vs SAP) or STEMI (1.6 +/- 0.4 relative units, p <0.05 vs UAP/NSTEMI). In contrast, the protein and mRNA expression of monocytic TIMP-1 levels was 4.5- to 4.7-fold lower in patients with STEMI than in the controls or those with SAP or UAP/NSTEMI (p <0.05). Changes in monocytic expression of MMP-9 and TIMP-1 tracked with the serum levels of MMP-9 and TIMP-1. The activity of serum MMP-9 correlated with the individual MMP-9/TIMP-1 ratio in the peripheral circulating monocytes (r(2) = 0.82, p <0.02). In conclusion, the progression of coronary artery disease was mirrored by an increasing MMP-9/TIMP-1 ratio in the peripheral circulating CD14+ monocytes and serum, respectively. Circulating monocytes displayed the same pattern of imbalance in the expression of MMP-9 and TIMP-1 as previously reported for monocyte-derived macrophages within atherosclerotic plaques, supporting the notion of atherosclerosis as a systemic inflammatory disease. (C) 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 2010;105:429-434)
引用
收藏
页码:429 / 434
页数:6
相关论文
共 30 条
[1]  
Abbate Antonio, 2003, Semin Vasc Med, V3, P375
[2]  
Ardans JA, 2002, J LEUKOCYTE BIOL, V71, P1012
[3]   Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis [J].
Bar-Or, A ;
Nuttall, RK ;
Duddy, M ;
Alter, A ;
Kim, HJ ;
Ifergan, I ;
Pennington, CJ ;
Bourgoin, P ;
Edwards, DR ;
Yong, VW .
BRAIN, 2003, 126 :2738-2749
[4]   Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease [J].
Blankenberg, S ;
Rupprecht, HJ ;
Poirier, O ;
Bickel, C ;
Smieja, M ;
Hafner, G ;
Meyer, J ;
Cambien, F ;
Tiret, L .
CIRCULATION, 2003, 107 (12) :1579-1585
[5]   Tissue inhibitors of metalloproteinases: evolution, structure and function [J].
Brew, K ;
Dinakarpandian, D ;
Nagase, H .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 2000, 1477 (1-2) :267-283
[6]   IDENTIFICATION OF 92-KD GELATINASE IN HUMAN CORONARY ATHEROSCLEROTIC LESIONS - ASSOCIATION OF ACTIVE ENZYME-SYNTHESIS WITH UNSTABLE ANGINA [J].
BROWN, DL ;
HIBBS, MS ;
KEARNEY, M ;
LOUSHIN, C ;
ISNER, JM .
CIRCULATION, 1995, 91 (08) :2125-2131
[7]   Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction [J].
Cavusoglu, Erdal ;
Ruwende, Cyril ;
Chopra, Vincent ;
Yanamadala, Sunitha ;
Eng, Calvin ;
Clark, Luther T. ;
Pinsky, David J. ;
Marmur, Jonathan D. .
AMERICAN HEART JOURNAL, 2006, 151 (05) :1101.e1-1101.e8
[8]   Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome [J].
Cheng, Min ;
Hashmi, Satwat ;
Mao, Xiaobo ;
Zeng, Qiu Tang .
CANADIAN JOURNAL OF CARDIOLOGY, 2008, 24 (05) :385-390
[9]   Quantitation and localization of matrix metalloproteinases and their inhibitors in human carotid endarterectomy tissues [J].
Choudhary, Salman ;
Higgins, Catherine L. ;
Chen, Iou Yih ;
Reardon, Michael ;
Lawrie, Gerald ;
Vick, G. Wesley, III ;
Karmonik, Christof ;
Via, David P. ;
Morrisett, Joel D. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (10) :2351-2358
[10]   LAMININ SIKVAV PEPTIDE INDUCTION OF MONOCYTE-MACROPHAGE PROSTAGLANDIN E(2) AND MATRIX METALLOPROTEINASES [J].
CORCORAN, ML ;
KIBBEY, MC ;
KLEINMAN, HK ;
WAHL, LM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (18) :10365-10368